We are live on
!
Find out more
BI
BVF Inc Portfolio holdings
AUM
$3.91B
1-Year Est. Return
304.52%
This Fund
S&P 500
This Quarter
Est. Return
+37.89%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$3.91B
AUM Growth
+$772M
(+25%)
Cap. Flow
-$38.9M
Cap. Flow
% of AUM
-0.99%
Top 10 Holdings %
Top 10 Hldgs %
65.59%
Holding
46
New
5
Increased
6
Reduced
9
Closed
2
Avg Time Held
12.8
quarters
Top 10 Avg Time Held
6.3
quarters
Top 20 Avg Time Held
8.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Xoma
XOMA
|
+$203M |
| 2 |
Q32 Bio
QTTB
|
+$19.6M |
| 3 |
Sagimet Biosciences
SGMT
|
+$17M |
| 4 |
Revolution Medicines
RVMD
|
+$15.8M |
| 5 |
Absci
ABSI
|
+$13.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kymera Therapeutics
KYMR
|
+$140M |
| 2 |
Mirum Pharmaceuticals
MIRM
|
+$53.1M |
| 3 |
Compass Therapeutics
CMPX
|
+$41.1M |
| 4 |
Palvella Therapeutics
PVLA
|
+$35M |
| 5 |
Septerna Inc
SEPN
|
+$32.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.86% |
| 2 | Financials | 0.14% |
| 3 | Miscellaneous | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
4D Molecular Therapeutics
FDMT
$683M
| $38.3M | 0.98% |
2,879,289
| – | – |
2020 Q4
22 quarters
|
|
|
27
Q32 Bio
QTTB
$240M
| $29.9M | 0.77% |
+2,350,000
| New | +$19.6M |
2026 Q2
0 quarters
|
|
28
Anteris Technologies
AVR
$629M
| $29.6M | 0.76% |
3,000,000
| – | – |
2026 Q1
1 quarter
|
|
29
Foghorn Therapeutics
FHTX
$110M
| $28.5M | 0.73% |
5,842,000
| – | – |
2024 Q2
8 quarters
|
|
|
30
Absci
ABSI
$1.56B
| $27.4M | 0.7% |
+2,361,674
| New | +$13.3M |
2026 Q2
0 quarters
|
|
31
Eledon Pharmaceuticals
ELDN
$190M
| $24.8M | 0.63% |
6,293,282
| – | – |
2019 Q2
28 quarters
|
|
32
Invivyd
IVVD
$190M
| $24.6M | 0.63% |
28,165,000
+8,640,000
| +44% | +$10.8M |
2025 Q4
2 quarters
|
|
|
33
Sagimet Biosciences
SGMT
$566M
| $19.3M | 0.49% |
+2,500,000
| New | +$17M |
2026 Q2
0 quarters
|
|
34
OnKure Therapeutics
OKUR
$95M
| $14.8M | 0.38% |
3,235,778
+1,256,806
| +64% | +$5.39M |
2026 Q1
1 quarter
|
|
35
Immunic
IMUX
$94M
| $11.8M | 0.3% |
765,295
-2
| -0% | -$25 |
2024 Q1
9 quarters
|
|
36
X4 Pharmaceuticals
XFOR
$258M
| $10.4M | 0.27% |
2,233,742
| – | – |
2025 Q3
3 quarters
|
|
37
ImageneBio Inc
IMA
$48.1M
| $6.55M | 0.17% |
1,110,002
| – | – |
2021 Q1
21 quarters
|
|
38
TScan Therapeutics
TCRX
$14.7M
| $5.45M | 0.14% |
5,564,290
| – | – |
2023 Q2
12 quarters
|
|
39
Research Alliance Corp III
RACC
$92.4M
| $5.35M | 0.14% |
+500,000
| New | +$5.21M |
2026 Q2
0 quarters
|
|
40
Molecular Partners
MOLN
$141M
| $5.15M | 0.13% |
1,353,968
| – | – |
2021 Q3
19 quarters
|
|
41
Tenax Therapeutics
TENX
$59.9M
| $4.94M | 0.13% |
339,549
| – | – |
2024 Q3
7 quarters
|
|
42
Entera Bio
ENTX
$433M
| $4.29M | 0.11% |
+2,425,000
| New | +$3.03M |
2026 Q2
0 quarters
|
|
43
Inventiva
IVA
$678M
| $2.59M | 0.07% |
686,040
| – | – |
2021 Q1
21 quarters
|
|
44
enGene Therapeutics Warrants
ENGNW
| $274K | 0.01% |
945,402
| – | – |
2023 Q4
10 quarters
|
|
|
45
Compass Therapeutics
CMPX
$154M
| – | – |
-7,764,842
| Closed | -$41.1M | – |
|
|
46
Septerna Inc
SEPN
$1.7B
| – | – |
-1,353,249
| Closed | -$32.5M | – |
|
Similar funds
LFCM
DCM
LNC
GL
AC
FFGIM
AIM
LCM
BVF Inc's Q2 2026 Portfolio in Review
As of Q2 2026, BVF Inc held 46 positions worth $3.91B, up 25% from $3.14B the previous quarter. Its ten largest holdings account for 66% of the portfolio.
BVF Inc's Q2 2026 filing shows 5 new, 6 increased, 9 reduced and 2 closed positions. Its largest new stake was Q32 Bio: 2,350,000 shares worth $29.9M. The largest sale was Kymera Therapeutics, an estimated $140M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials and Miscellaneous.
- BVF Inc's largest Q2 2026 buy was Q32 Bio: 2,350,000 shares worth $29.9M.
- BVF Inc added most to Xoma in Q2 2026, an estimated $203M increase.
- BVF Inc's biggest Q2 2026 reduction was Kymera Therapeutics, cutting an estimated $140M.
- BVF Inc fully exited Compass Therapeutics in Q2 2026, selling an estimated $41.1M.
- BVF Inc's ten largest holdings make up 66% of its $3.91B portfolio in Q2 2026.
- BVF Inc opened 5 new positions and closed 2 in Q2 2026.
- BVF Inc's portfolio value rose 25% quarter-over-quarter to $3.91B.
Based on BVF Inc's 13F filing for Q2 2026, filed 14 Aug 2026.